RecruitingNot applicableNCT06479317
The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yunfeng Cheng
- Principal Investigator
- Yunfeng ChengShanghai Zhongshan Hospital
- Intervention
- Hydroxychloroquine Oral Tablet(drug)
- Enrollment
- 129 enrolled
- Eligibility
- 15-75 years · All sexes
- Timeline
- 2024 – 2026
Study locations (7)
- Shanghai Zhongshan Hospital, Shanghai, Shanghai Municipality, China
- Zhongshan Wusong Hospital, Fudan University, Shanghai, Shanghai Municipality, China
- Shanghai Jinshan Hospital, Shanghai, Shanghai Municipality, China
- Zhongshan Qingpu Hospital, Fudan University, Shanghai, Shanghai Municipality, China
- Health and Humanity Research Centre, Hongkong, China., Hong Kong, Hong Kong
- Dr. Stanley Ho Medical Foundation, Macao, Macau
- University Hospital, Macau University of Science and Technology., Macao, Macau
Collaborators
Shanghai Zhongshan Hospital · Shanghai Jinshan Hospital · Zhongshan Qingpu Hospital, Fudan University · Zhongshan Wusong Hospital, Fudan University · Macau University of Science and Technology Hospital · Health and Humanity Research Centre, Hongkong · Dr. Stanley Ho Medical Foundation, Macau
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06479317 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation